Twist Bioscience Quarterly Income Statement
NASDAQ: TWSTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Twist Bioscience revenue and earnings
In the quarter ended Jun 30, 2026, Twist Bioscience generated $118.4 million in revenue, up 23.2% from the same quarter a year earlier. Twist Bioscience reported a net loss of $35.1 million, compared with net income of $20.4 million a year earlier. Gross margin was 52.8% (down from 53.4%) and operating margin -30.6%.
Diluted earnings per share came in at -$0.56, down from $0.33.
Summary generated from market data by MetaCap's automated system. Methodology
Twist Bioscience income statement (quarterly)
| Quarter (USD) | Q3 20262026-06-30 | Q2 20262026-03-31 | Q1 20262025-12-31 | Q4 20252025-09-30 | Q3 20252025-06-30 | Q2 20252025-03-31 | Q1 20252024-12-31 | Q4 20242024-09-30 | Q3 20242024-06-30 | Q2 20242024-03-31 | Q1 20242023-12-31 | Q4 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 118.38M | 110.72M | 103.70M | 99.01M | 96.06M | 92.79M | 88.71M | 84.71M | 81.46M | 75.30M | 71.50M | 66.95M |
| Revenue growth (YoY) | +23.24% | +19.31% | +16.89% | +16.88% | +17.91% | +23.23% | +24.08% | +26.53% | +27.81% | +25.13% | +31.81% | +16.82% |
| Cost of Revenue | 55.92M | 53.59M | 49.73M | 48.17M | 44.76M | 46.77M | 45.87M | 46.48M | 46.19M | 44.42M | 42.54M | 42.42M |
| Gross Profit | 62.45M | 57.12M | 53.97M | 50.84M | 51.30M | 46.03M | 42.84M | 38.23M | 35.27M | 30.88M | 28.96M | 24.52M |
| Operating Expenses | 98.73M | 102.98M | 86.87M | 80.77M | 81.42M | 87.59M | 77.48M | 74.28M | 124.19M | 79.77M | 75.94M | 74.63M |
| Research & Development | 18.02M | 19.70M | 17.13M | 17.01M | 18.05M | 23.92M | 21.31M | 21.13M | 22.47M | 24.15M | 23.10M | 23.75M |
| Selling, General & Admin | 80.71M | 76.08M | 69.74M | 63.76M | 63.37M | 63.67M | 56.18M | 53.14M | 56.79M | 55.62M | 52.84M | 47.39M |
| Operating Income | -36.28M | -45.86M | -32.90M | -29.93M | -30.12M | -41.56M | -34.64M | -36.04M | -88.92M | -48.89M | -46.98M | -50.11M |
| Interest Expense | — | — | — | — | — | 143.00K | 24.00K | 29.00K | 0 | 0 | 0 | 1.00K |
| Other Income (Expense) | 40.00K | 175.00K | 471.00K | 420.00K | -836.00K | -394.00K | -93.00K | -2.33M | -121.00K | -199.00K | -31.00K | -250.00K |
| Pretax Income | -34.74M | -43.98M | -30.25M | -26.88M | 20.58M | -39.15M | -31.50M | -34.75M | -85.38M | -45.15M | -42.89M | -46.47M |
| Income Tax | 311.00K | 43.00K | 253.00K | 257.00K | 191.00K | 175.00K | 97.00K | -96.00K | 191.00K | 345.00K | 120.00K | -222.00K |
| Net Income | -35.05M | -44.02M | -30.51M | -27.14M | 20.39M | -39.33M | -31.59M | -34.66M | -85.57M | -45.49M | -43.01M | -46.24M |
| Net Income growth (YoY) | -271.90% | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.56 | -0.71 | -0.50 | -0.45 | 0.34 | -0.66 | -0.53 | -0.59 | -1.47 | -0.79 | -0.75 | -0.81 |
| EPS (Diluted) | -0.56 | -0.71 | -0.50 | -0.44 | 0.33 | -0.66 | -0.53 | -0.59 | -1.47 | -0.79 | -0.75 | -0.81 |
| Shares Outstanding (Basic) | 62.40M | 61.70M | 61.08M | — | 59.99M | 59.65M | 59.16M | — | 58.15M | 57.78M | 57.50M | — |
| Shares Outstanding (Diluted) | 62.40M | 61.70M | 61.08M | — | 61.16M | 59.65M | 59.16M | — | 58.15M | 57.78M | 57.50M | — |
| EBITDA | -29.50M | -39.45M | -26.71M | -23.93M | -24.05M | -35.16M | -28.26M | -29.39M | -80.62M | -40.59M | -38.81M | -41.61M |
| Gross Margin | 52.76% | 51.59% | 52.05% | 51.35% | 53.40% | 49.60% | 48.29% | 45.13% | 43.30% | 41.01% | 40.51% | 36.63% |
| Operating Margin | -30.65% | -41.42% | -31.73% | -30.23% | -31.36% | -44.79% | -39.05% | -42.55% | -109.15% | -64.92% | -65.70% | -74.85% |
| Net Margin | -29.61% | -39.76% | -29.42% | -27.41% | 21.23% | -42.38% | -35.61% | -40.91% | -105.04% | -60.41% | -60.15% | -69.08% |
This table shows 12 quarterly periods of Twist Bioscience's income statement, from Q3 2026 back to Q4 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TWST's reporting calendar. What is a income statement?